메뉴 건너뛰기




Volumn 17, Issue SUPPL. 7, 2006, Pages

New strategies in colon cancer adjuvant therapy

Author keywords

Adjuvant therapy; Colon cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT; VASCULOTROPIN;

EID: 33745623972     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl951     Document Type: Article
Times cited : (5)

References (11)
  • 1
    • 0028956045 scopus 로고    scopus 로고
    • Fluorouracil plus levamisole as effective adjuvant therapy after resection in stage III colon carcinoma: A final report
    • Moertel CG, Fleming TR, MacDonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection in stage III colon carcinoma: A final report. Ann Intern Med 122: 321-326.
    • Ann Intern Med , vol.122 , pp. 321-326
    • Moertel, C.G.1    Fleming, T.R.2    MacDonald, J.S.3
  • 2
    • 0024347268 scopus 로고
    • Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
    • Poon MA, O'Connell W, Moertel CG et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-1418.
    • (1989) J Clin Oncol , vol.7 , pp. 1407-1418
    • Poon, M.A.1    O'Connell, W.2    Moertel, C.G.3
  • 3
    • 0027436244 scopus 로고
    • The benefit of leucovorin modulated fluorouracil as post operative adjuvant therapy for primary colon cancer: Results from NSABP c-03
    • Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin modulated fluorouracil as post operative adjuvant therapy for primary colon cancer: Results from NSABP c-03. J Clin Oncol 1993; 11: 1879-1887.
    • (1993) J Clin Oncol , vol.11 , pp. 1879-1887
    • Wolmark, N.1    Rockette, H.2    Fisher, B.3
  • 4
    • 0042887580 scopus 로고    scopus 로고
    • Semimonthly versus monthly regimen of fluorouracil and leucovorin administred for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial
    • Andre T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administred for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol 2003; 21: 2896-2903.
    • (2003) J Clin Oncol , vol.21 , pp. 2896-2903
    • Andre, T.1    Colin, P.2    Louvet, C.3
  • 5
    • 2542615200 scopus 로고    scopus 로고
    • Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer
    • Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
    • (2004) N Engl J Med , vol.350 , pp. 2343-2351
    • Andre, T.1    Boni, C.2    Mounedji-Boudiaf, L.3
  • 6
    • 24344476396 scopus 로고    scopus 로고
    • A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07
    • Abstr 3500
    • Wolmark N, Wieand HS, Kuebler JP. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc Am Soc Clin Oncol 2005; Abstr 3500.
    • (2005) Proc Am Soc Clin Oncol
    • Wolmark, N.1    Wieand, H.S.2    Kuebler, J.P.3
  • 7
    • 21344456269 scopus 로고    scopus 로고
    • Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid(IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)
    • Abstr 8
    • Van Cutsem E, Labianca R, Hossfeld D et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid(IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Proc Am Soc Clin Oncol 2005; 23: Abstr 8.
    • (2005) Proc Am Soc Clin Oncol , vol.23
    • Van Cutsem, E.1    Labianca, R.2    Hossfeld, D.3
  • 8
    • 9144238357 scopus 로고    scopus 로고
    • Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial
    • Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-1743.
    • (2003) Ann Oncol , vol.14 , pp. 1735-1743
    • Scheithauer, W.1    McKendrick, J.2    Begbie, S.3
  • 9
    • 10644243163 scopus 로고    scopus 로고
    • A phase III trial omparing oral UFT to FULV in stage II and III carcinomaof colon: Results of NSABP C-06
    • Abstr 3508
    • Wolmark N, Wieand S, Lembersky B et al. A phase III trial omparing oral UFT to FULV in stage II and III carcinomaof colon: Results of NSABP C-06. Proc Am Soc Clin Oncol 2004; 23: Abstr 3508.
    • (2004) Proc Am Soc Clin Oncol , vol.23
    • Wolmark, N.1    Wieand, S.2    Lembersky, B.3
  • 10
    • 33745598215 scopus 로고    scopus 로고
    • Meta-Analysis Group in Cancer (MAGIC) Progression-Free Survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials
    • Abstr 3513
    • Buyse M, Burzykowski T, Carroll K et al. Meta-Analysis Group in Cancer (MAGIC) Progression-Free Survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials. Proc Am Soc Clin Oncol 2005; 23: Abstr 3513.
    • (2005) Proc Am Soc Clin Oncol , vol.23
    • Buyse, M.1    Burzykowski, T.2    Carroll, K.3
  • 11
    • 33644834827 scopus 로고    scopus 로고
    • Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
    • Sargent DJ, Wieand S, Benedetti J et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-8670.
    • (2005) J Clin Oncol , vol.23 , pp. 8664-8670
    • Sargent, D.J.1    Wieand, S.2    Benedetti, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.